Ibogaine treatment with digital support for opioid use disorder
Part of Mental health clinical trials.
This trial tests whether a single treatment with ibogaine, a plant-based medicine, combined with a year of app and wearable support, helps people reduce or stop opioid use. It is for adults who have not had success with other treatments and are seeking a new option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- You have moderate or severe opioid use disorder and are currently dependent on opioids.
- You have tried other treatments but they haven't worked well enough, or you've had a relapse.
- You must be willing to stay in a clinic for the treatment and monitoring period.
- You need to be willing to use a study-provided smartwatch and smartphone for 12 months of follow-up.
- Your heart, liver, and kidney function must be within safe limits, and you must not be taking certain medications or supplements.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies a program meant to improve treatment access and support recovery for people with opioid use disorder who also have mental health symptoms. It may help if you are new to the program or recently relapsed, or if mental health symptoms have worsened—even without a relapse.
This trial tests whether a combination of buprenorphine (through your care plan) and a monthly extended-release naltrexone (XR-NTX) shot can help prevent opioid relapse. It may help people who are ready to move toward a naltrexone-based relapse-prevention treatment after detox.
This trial tests a physical device (ADTPM 1) to help manage withdrawal symptoms in people who are dependent on opioids. The goal is to see if the device can safely reduce withdrawal discomfort.
This Phase 1 study tests how adding psilocybin to a standard opioid treatment (buprenorphine-naloxone) affects recovery and symptoms in people with moderate-to-severe opioid use disorder. It may help researchers understand whether this combination is safe and beneficial alongside medication for opioid withdrawal and cravings.
This Phase 3 study tests whether using smartphones can help people with opioid-use disorder stick with treatment and recover more successfully. It focuses on people starting or already in treatment using methadone or buprenorphine, with support delivered through the study app or messages.
This trial tests whether psilocybin can help people recovering from opioid use disorder while living at a residential treatment center. If you are already taking buprenorphine/naloxone (Suboxone), methadone, or have received Sublocade, this study may be an option for you.
Hear when a new Opioid Use Disorder trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.